Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 - Eichhorn, P J; Gili, M; Scaltriti, M (Cancer Res, 2008)
et al.